Long term psoriasis control with guselkumab versus secukinumab and ixekizumab among bio- experienced patients: analysis of drug persistence in large claims database

被引：0
|
作者：
Zhdanava, Maryia [1 ]
Fitzgerald, Timothy [2 ]
Pilon, Dominic [1 ]
Teneralli, Rachel [3 ]
Shah, Aditi [1 ]
Holiday, Christopher [1 ]
Lefebvre, Patrick [1 ]
Feldman, Steven [4 ]
机构：
[1] Grp Analyse, Montreal, PQ, Canada
[2] Janssen Sci Affairs LLC, Titusville, NJ USA
[3] Janssen Global Serv LLC, Titusville, NJ USA
[4] Wake Forest Sch Med, Winston Salem, NC USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：AB188 / AB188
页数：1
相关论文
共 24 条
  • [1] Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
    Fitzgerald, Timothy
    Zhdanava, Maryia
    Pilon, Dominic
    Shah, Aditi
    Hilts, Annalise
    Lefebvre, Patrick
    Feldman, Steven R. R.
    [J]. DERMATOLOGY AND THERAPY, 2023, 13 (04) : 1053 - 1068
  • [2] Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
    Timothy Fitzgerald
    Maryia Zhdanava
    Dominic Pilon
    Aditi Shah
    Annalise Hilts
    Patrick Lefebvre
    Steven R. Feldman
    [J]. Dermatology and Therapy, 2023, 13 : 1053 - 1068
  • [3] Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
    Timothy Fitzgerald
    Maryia Zhdanava
    Dominic Pilon
    Aditi Shah
    Patrick Lefebvre
    Steven R. Feldman
    [J]. Dermatology and Therapy, 2023, 13 : 2917 - 2923
  • [4] Response to the Letter to the Editor: Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
    Fitzgerald, Timothy
    Zhdanava, Maryia
    Pilon, Dominic
    Shah, Aditi
    Lefebvre, Patrick
    Feldman, Steven R.
    [J]. DERMATOLOGY AND THERAPY, 2023, 13 (11) : 2917 - 2923
  • [5] Comparison of long-term treatment patterns between ixekizumab and secukinumab users among biologic-experienced psoriasis patients
    Blauvelt, Andrew
    Shi, Nianwen
    Burge, Russel
    Ridenour, Terri L.
    Somani, Najwa
    Zhu, Baojin
    Atiya, Bilal
    Lew, Carolyn R.
    Kern, Scott A.
    Zimmerman, Nicole M.
    Murage, Mwangi J.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB114 - AB114
  • [6] Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
    Blauvelt, Andrew
    Garrelts, Alyssa
    Malatestinic, William
    Birt, Julie
    Zhu, Baojin
    Feely, Meghan
    [J]. DERMATOLOGY AND THERAPY, 2023, 13 (11) : 2911 - 2916
  • [7] Letter to the Editor: Response to Fitzgerald T et al. Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA
    Andrew Blauvelt
    Alyssa Garrelts
    William Malatestinic
    Julie Birt
    Baojin Zhu
    Meghan Feely
    [J]. Dermatology and Therapy, 2023, 13 : 2911 - 2916
  • [8] Long-term efficacy, safety, and drug survival of secukinumab in patients with psoriasis in Turkey: a retrospective analysis of real-world experience
    Yildirim, Fatma Elif
    Hapa, Fatma Asli
    [J]. POSTEPY DERMATOLOGII I ALERGOLOGII, 2024, 41 (01): : 49 - 55
  • [9] LONG-TERM NEUROLOGIC SEQUELAE AMONG PATIENTS WITH VARYING COVID-19 SEVERITY: AN ADMINISTRATIVE CLAIMS DATABASE ANALYSIS
    Dhangar, I
    Ahlawat, R.
    Veeranki, P.
    Anderson, A.
    McPheeters, J. T.
    Singh, K. P.
    [J]. VALUE IN HEALTH, 2023, 26 (06) : S383 - S383
  • [10] Long-Term Statin Persistence is Poor Among High-Risk Patients in a Real-World Administrative Claims Analysis
    Toth, Peter
    Granowitz, Craig
    Hull, Michael
    Liassou, Djibril
    Anderson, Amy
    Philip, Sephy
    [J]. CIRCULATION, 2017, 136
123